The key NHS targets that have never been met

The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled…

The latest variant of the COVID-19 virus, JN.1, is now responsible for an estimated 15% to 29% of cases in the U.S. as of Dec. 8, according to a posted update from the Centers for Disease Control and Prevention (CDC). JN.1, which is currently the country’s fastest growing variant, is expected to continue to increase…

As the weather gets warmer, pants turn to shorts, long sleeves turn to tank tops and sensible waterproof winter boots turn to cute strappy sandals. If you’re planning on showing your feet to the world or have a sunny vacation on the calendar, you’re likely in dire need of a pedicure. Before you make an…

Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…

Business & FinanceDealsHealth 21 July 2023, 6:41 pm 1 minute Reuters exclusively reported that Thorne HealthTech Inc (THRN.O), a provider of at-home health tests and nutritional supplements, is exploring a sale.  Market Impact Thorne’s shares ended trading on Friday up 12.9% at $5.95 on the news, giving the company a market value of $320 million….

Author Ellie Middleton on her late ADHD and autism diagnoses.